These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, Holland-Letz T, Giesel FL, Kratochwil C, Haufe S, Haberkorn U, Zechmann CM. Eur J Nucl Med Mol Imaging; 2013 Apr; 40(4):486-95. PubMed ID: 23179945 [Abstract] [Full Text] [Related]
9. Matched-Pair Comparison of 68Ga-PSMA-11 and 18F-rhPSMA-7 PET/CT in Patients with Primary and Biochemical Recurrence of Prostate Cancer: Frequency of Non-Tumor-Related Uptake and Tumor Positivity. Kroenke M, Mirzoyan L, Horn T, Peeken JC, Wurzer A, Wester HJ, Makowski M, Weber WA, Eiber M, Rauscher I. J Nucl Med; 2021 Aug 01; 62(8):1082-1088. PubMed ID: 33277394 [Abstract] [Full Text] [Related]
15. The Contribution of Multiparametric Pelvic and Whole-Body MRI to Interpretation of 18F-Fluoromethylcholine or 68Ga-HBED-CC PSMA-11 PET/CT in Patients with Biochemical Failure After Radical Prostatectomy. Metser U, Chua S, Ho B, Punwani S, Johnston E, Pouliot F, Tau N, Hawsawy A, Anconina R, Bauman G, Hicks RJ, Weickhardt A, Davis ID, Pond G, Scott AM, Tunariu N, Sidhu H, Emmett L. J Nucl Med; 2019 Sep 01; 60(9):1253-1258. PubMed ID: 30902875 [Abstract] [Full Text] [Related]